ⅣMulticenter Randomized Positive Drug Controlled Clinical Trial of aFGF and bFGF in the Treatment ofⅢDegree Burns
Abstract：Objective:To compare recombinant human acidic fibroblast growth factor (rh-aFGF) and basic differences in the clinical efficacy of a fibroblast growth factor (bFGF) treatment ofⅢdegree burns. Method:The study enrolled four hospital 47 cases of deep burns patients in both groups were given admission within 72 h corresponding tangential excision,skin graft,anti-infective and nutritional support. AFGF treatment group of 24 patients given treatment (tangential excision after washing,skin graft treatment,postoperative dressing). BFGF control group of 23 patients received treatment with aFGF administration method of administration method exactly. Two continuous treatment 21 days,observe wound healing,skin flap survival and adverse events. Result:The complete healing time,30 d healing rate of skin graft survival area were (44.2±4.2)d,75.0%,(94.7±5.8)%,the control group were(48.8±4.6)d,43.5%,(87.4±6.4)%. 1 patient (4.2%) occurred sepsis in treatment group,the control group had five(21.7%).There were no adverse reactions occur in treatment process. Conclusion:rh-aFGF to promote healing and improve skin flap survival role in improving patients with severe burns to heal than bFGF.
Keywords：Acidic fibroblast growth factorBasic fibroblast growth factorⅢdegree burns
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：2( 1-2 )